Showing posts with label Biosimilars Market. Show all posts
Showing posts with label Biosimilars Market. Show all posts

Monday, 18 January 2021

CAGR 7.5% Growth Predicted in Biosimilars Market by 2025 with Top Leading Players and Technology

Biosimilars Market-Highlights

The global biosimilars market is expected to exhibit a strong 7.5% CAGR over the forecast period from 2019 to 2025, according to the latest research report from Market Research Future (MRFR). The global biosimilars market was valued at USD 13.4 billion in 2018. 

Get Free Sample Copy Of Biosimilars Market @ https://www.marketresearchfuture.com/sample_request/1329 

Biosimilars are biological medicines that are highly similar to another already approved medicine. The patent expiry of several blockbuster drugs has been a major driver for the global biosimilars market over the last few years, as this has driven the demand for generics and other alternatives to blockbuster drugs. This is likely to remain a major driver for the global biosimilars market over the forecast period, with several blockbuster drugs expected to lose their patents in the coming years, leading to a growing demand for alternatives. Due to the high profitability of biosimilars, many pharmaceutical companies have invested significantly in the development of biosimilars in the last few years. Biosimilars have become a highly useful and lucrative addition to the portfolio of pharmaceutical giants in the last few years. This is also likely to remain a key driver for the global biosimilars market over the forecast period. 

The growing prevalence of chronic diseases is also likely to be a major driver for the global biosimilars market over the forecast period. The increasing prevalence of orthopedic, hematological, oncological, and neurological diseases that take a long time to fix has been a boon for the biosimilars market, as this has driven the demand for effective biological drugs to treat the diseases. The increasing demand from patients for biological products, which are viewed as being healthier and more effective than synthetic products, is also likely to be a major driver for the global biosimilars market over the forecast period. Noting the growing demand for biosimilars, the U.S. FDA has approved numerous biosimilars drugs over the last few years. This has also been a major driver for the global biosimilars market and is likely to remain a key driver for the market over the forecast period. 

Biosimilars Market Competitive Leaderboard:

Leading players in the global biosimilars market include Mylan Inc., Stada Arzneimittel AG, Cipla Ltd., Actavis Inc., Hospira Inc., Eli Lily and Company, Samsung Biologics, Celltrion, Dr. Reddy’s Laboratories, Biocon, Amgen Inc., Teva Pharmaceuticals, Sandoz International, and Pfizer. Major players in the global biosimilars market are likely to focus on product expansion and development over the forecast period. Developing new, varied biosimilars for multiple diseases is likely to remain a profitable venture for players in the biosimilars market over the forecast period. 

Biosimilars Market Segmentation:

The global biosimilars market is segmented on the basis of product, application, end user, and region. 

By product type, the global biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further sub-segmented into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin. The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the incidence of chronic diseases, diabetes, and growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening.  

By application, the global biosimilars market is segmented into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. The blood disorders segment is expected to exhibit growth at a high growth rate over the forecast period due to the growing realization of the usability of biosimilars in treating blood disorders. 

By end use, the global biosimilars market is segmented into hospitals and clinics, research institutes, and others. Hospitals and clinics are likely to hold the largest share in the global biosimilars market over the forecast period. 

Biosimilars Market Regional Analysis:

Europe is expected to dominate the global biosimilars market over the forecast period, followed by North America. Increasing product launches and supportive schemes from governments in the region are the major driver for the Europe and North America biosimilars markets. 

OBTAIN RESEARCH REPORT DETAILS WITH TOC @

https://www.marketresearchfuture.com/reports/biosimilars-market-1329

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.


Tuesday, 5 January 2021

Regional Analysis on Biosimilars Market Forecast from 2018-2025

 Biosimilars Market – Overview

As biosimilars show a similar effect as compared to generic medicines, they are growing their popularity at an increased pace. Market concentrated reports associated with the healthcare industry amid others recently have been made available by Market Research Future which issues reports on this industry.Biosimilars Market Size is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.

Free Sample Copy of Biosimilars Market With Considering Coivd19 Impact on this Market @https://www.marketresearchfuture.com/sample_request/1329

As the processes used to make generic medicines can’t be used to develop biosimilar medicines, the market for biosimilars is expanding positively. Increase in the analytical studies has prompted the increased growth of the biosimilars market in the forecast period. Sizeable investments in multiple state-of-the-art facilities that are developing biosimilars has prompted significant growth in the market. The market is motivated majorly due to the different diseases that are being diagnosed in recent times. Increased level of clinical trials have influenced the development of the market considerably. The focus of this segment is currently on ensuring the release of biosimilar drugs into the market to treat a wider spectrum of diseases.

Industry Segments 

The market for biosimilars globally is segmented on the basis of product into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and other.  The Recombinant glycosylated proteins are additionally sub segmented into monoclonal antibody (mAb) and EPO. Recombinant non-glycosylated proteins is sub segmented into growth hormones, insulin and other.  On the basis of application, the market is segmented into immune diseases, blood related disorders, oncology and other. On the basis of manufacturing, the market is segmented into in-house manufacturing and contract manufacturing.

Biosimilars Market- Detailed Regional Analysis

The regional analysis of the market for biosimilars includes APAC, North America, Europe, Middle East and Africa. The European region has been guiding the market for the biosimilars. Rising geriatric population and growing prevalence of diseases have led to the growth of this market in the European region. North America has the second top market followed by the Asia Pacific region. The Asia Pacific biosimilars market is anticipated to grow at a CAGR of 27.8 percent in the forecast period.

Biosimilars Market- Global Competitive Analysis

The competitors in the market are trying to get ahead commercially by making sure that demand and supply are in balance. The momentum of the market’s progress has changed the competitive backdrop of the market. The competitors in the market are persistently trying to establish leading market positions through new policies and strategies. The experienced management in the companies operating in the market are creating business models which can bring about a fruitful phase of development. The key trends and players have established a positive tone for development. The contenders in the market are also leveraging their competitive advantages to secure their growth in the market. The market development by competitors also encompasses strong risk management strategies.

Sandoz International GmbH (Germany), Celltrion, Inc. (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Biocon Ltd. (India), Astra Zeneca (UK),  Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Novartis (Switzerland), Accord Healthcare (UK), Eli Lilly (US), Teva Pharmaceuticals Industries Ltd. (Israel), Dr. Reddy’s Laboratories Ltd. (India) and Samsung Bioepis (South Korea).

Industry Updates:

June 2018 Mylan NV has recently achieved a major milestone recently by winning an approval from the U.S. Food and Drug Administration aimed at a biosimilar version of Neulasta which is an anti-infective used for patients suffering from breast cancer treatment. The pharmaceutical giant plans to launch the product, Fulphila, in the coming weeks. The McClintic Coates said that a big part of the FDA’s approval of Mylan’s biosimilar cancer therapy, Fulphila, is attributed to the drugmaker’s Morgantown-based research and development capabilities. Fulphila would signify the first alternative and more reasonable treatment option to Neulasta for oncology patients.

OBTAIN RESEARCH REPORT DETAILS WITH TOC @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:                                

Akash Anand                                                                   

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com